Balancing Innovation: India’s Views for Pharmaceuticals in the Efta Trade Deal
IIPRD
APRIL 2, 2024
INDIA AND EFTA: PHARMA FRONT From the perspective of India, a leading producer of generic medicines, contractual agreements with developed nations raise several key considerations. With India being a major producer of generic drugs, stricter IP rules advocated by EFTA countries could pose a challenge.
Let's personalize your content